GE BioPharma sale to Danaher is complete

By The Science Advisory Board staff writers

April 1, 2020 -- The divestment of GE's BioPharma business unit to Danaher is complete, according to an announcement by both companies on March 31.

As part of Danaher, the business will be called Cytiva and will operate as a standalone company within Danaher's Life Sciences segment.

The deal, which was originally announced in February 2019, was completed with a cash consideration of around $20 billion to GE as well as Danaher's assumption of certain pension liabilities.

FTC greenlights $20B GE-Danaher deal
Following an agreement with the U.S. Federal Trade Commission (FTC), GE Healthcare Life Sciences is moving forward with the sale of its GE Biopharma business...

Copyright © 2020 scienceboard.net


Register below for our weekly Letter from the Editor to receive the latest Science news and insights.
Email
Conferences
BioProcess International Europe
July 13-17
Central European Time Zone (CET) Netherlands
2020 ACCP Annual Meeting
September 20-22
Bethesda, Maryland United States
Bioprocess International West
September 21-24
Eastern Standard Time Zone (EST) United States
Connect
Science Advisory Board on LinkedIn
Science Advisory Board on Facebook
Science Advisory Board on Twitter